



CELGENE @ ASCO 2017



Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017.

Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research. In multiple myeloma, abstracts will continue to support the role of Celgene's **IMiD® therapies** as the foundation of multiple myeloma research, including in the maintenance setting. Key data readouts include the following:

- Study evaluating the investigational R2 regimen (REVLIMID® and rituximab combination), in previously-treated follicular lymphoma.
- Two studies in the ABOUND program evaluating ABRAXANE®(nab-paclitaxel) in NSCLC
- Phase I dose escalation and expansion study of IDHIFA®(enasidenib) in patients with mutant-IDH2 relapsed/refractory acute myeloid leukemia,
- First clinical study of anti-BCMA CAR-T therapy bb2121 in multiple myeloma,
- Study of CAR-T therapy JCAR017 in previously-treated aggressive b-cell NHL

Key Trial Readouts

Newly diagnosed multiple myeloma	<ul style="list-style-type: none"> • Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MM): MMY1001 study (Abstract 8000) • Lenalidomide, adriamycin and dexamethasone versus bortezomib, lenalidomide and dexamethasone prior to scheduled stem cell transplant in newly diagnosed MM (Abstract 8001) • Phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed MM (Abstract 8002) • Lenalidomide induction and maintenance therapy for myeloma: Results of the Myeloma XI Study (Abstract 8009) • Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients with newly diagnosed MM: Connect® MM Registry (Abstract 8023)
Relapsed/Refractory Multiple Myeloma	<ul style="list-style-type: none"> • Phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (Abstract 8007) • Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (Ben-Pom-d) in patients with relapsed/refractory MM (Abstract 8008) • Pembrolizumab plus lenalidomide and low-dose dexamethasone for relapsed/refractory MM: Efficacy and biomarker analyses (Abstract 8015) • First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory MM: Updated results (Abstract 3010) • Phase II study of pomalidomide + low-dose dexamethasone following 2L lenalidomide-based treatment in patients with relapsed or refractory MM: An updated analysis of efficacy and safety (Abstract 8027)
Maintenance of multiple myeloma	<ul style="list-style-type: none"> • Lenalidomide vs. placebo maintenance after stem cell transplant for patients with MM: OS & PFS adjusted for Tx crossover: CALGB/ECOG 100104 Alliance study (Abstract 8037) • Impact of post-autologous stem cell transplant maintenance therapy on outcomes in pts with newly diagnosed MM using large prospective community-based Connect® MM Registry (Abstract 8040)
Acute Myeloid Leukemia	<ul style="list-style-type: none"> • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia: Results of a phase I dose-escalation and expansion study (Abstract 7004) • Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (Abstract 7004) • Molecular genetic testing patterns for patients with newly diagnosed AML enrolled in the CONNECT® MDS/AML Disease Registry (Abstract 7022)
Lymphoma/CLL	<ul style="list-style-type: none"> • Phase IIIb randomized study of lenalidomide+ rituximab followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (Abstract 7502) • Genetic risk-stratified, phase II study of fludarabine/antibody combinations in symptomatic, untreated CLL: Final results of Cancer and Leukemia Group B: CALGB 10404 (Abstract 7503) • CR rates in relapsed/refractory aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017: TRANSCEND NHL 001 (Abstract 7513)
NSCLC	<ul style="list-style-type: none"> • Safety & efficacy of nab-P based therapy in pts with NSCLC and ECOG PS2: ABOUNDPS2 (Abstract 9058) • Safety & efficacy of nab-P/carbo in elderly pts with advanced NSCLC (ABOUND.70+) (Abstract 9059) • Atezolizumab plus platinum-based chemo in NSCLC: Update from phase Ib study (Abstract 9092) • Nivo + nab-P + carbo in pts with NSCLC: Interim results from PI study (Waterhouse) Abstract 9095
Biliary tract cancer	<ul style="list-style-type: none"> • Phase II trial of gemcitabine, cisplatin, and nab-paclitaxel in advanced biliary tract cancers (Abstract 4018)

CORPORATE COMMUNICATIONS



"We are part of an extremely exciting time in cancer research, where accelerating deep insights into the biology of disease and tumor microenvironment are leading to approaches that have the potential to make a major impact on patients' lives," said Michael Pehl, President, Hematology and Oncology for Celgene. "The studies being shared at ASCO this year reinforce our commitment to developing and delivering innovative treatment options to patients with cancer around the world."